Drug treatment of epilepsy: Options and limitations

Epilepsy and Behavior

Volumn 15, Issue 1, 2009, Pages 56-65

  Schmidt, Dieter ^a  

^a Epilepsy Research Group   (Germany)

Author keywords

Adverse drug effects; Choice of AEDs; Drug resistant epilepsy; Psychiatric comorbidity; Starting AEDs; Stopping AEDs

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BROMIDE; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORAZEPAM; MEPHENYTOIN; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; ANXIETY DISORDER; APLASTIC ANEMIA; ARTICLE; BEDTIME DOSAGE; BEHAVIOR DISORDER; BRAIN DISEASE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE CONTROL; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ELDERLY CARE; EPILEPSY; EPILEPTIC STATE; GASTROINTESTINAL DISEASE; HUMAN; HYPONATREMIA; LEUKOPENIA; LIVER FAILURE; MEDICAL DECISION MAKING; MEGALOBLASTIC ANEMIA; MENTAL DISEASE; MORBIDITY; MORTALITY; NEPHROLITHIASIS; OSTEOPOROSIS; PANCREATITIS; PATIENT MONITORING; PSYCHOSIS; QUALITY OF LIFE; RASH; RISK BENEFIT ANALYSIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION;

AGE FACTORS; ANIMALS; ANTICONVULSANTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 67349117806     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.02.030     Document Type: Article

References (36)

1. In: Levy R.H., Mattson R.H., Meldrum B., and Perucca E. (Eds). Antiepileptic drugs. 5th ed. (2002), Lippincott, Williams & Wilkins, Philadelphia
2. Shorvon S. Handbook of epilepsy treatment (2000), Blackwell Science, Oxford
3. In: Engel Jr. J., and Pedley T. (Eds). Epilepsy: a comprehensive textbook. 2nd ed. vols. 1-3 (2007), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia
4. Marson A., Jacoby A., Johnson A., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 365 (2005) 2007-2013
5. Patsalos P.N., and Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2 (2003) 347-356
6. Strolin-Benedetti M. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14 (2000) 301-309
7. Zaccara G., Franciotta D., and Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48 (2007) 1223-1244
8. Alvestad S., Lydersen S., and Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 48 (2007) 1360-1365
9. Elger C.E., and Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 12 (2008) 510-539
10. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs: I. Treatment of refractory epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 410-423
11. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs: I: Treatment of new-onset epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 401-409
12. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
13. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 24 369 (2007) 1016-1026
14. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., and Schiemann-Delgado J. For the N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 (2008) 607-616
15. Schmidt D., and Gram L. Monotherapy versus polytherapy in epilepsy. CNS Drugs 3 (1995) 194-208
16. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-339
17. Hakkarainen H. Carbamazepine vs diphenylhydantoin vs. their combination in adult epilepsy. Neurology 30 (1980) 354
18. Beghi E., Gatti G., Tonini C., et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 57 (2003) 1-13
19. Schiller Y., and Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 70 (2008) 54-65
20. Hauser WA. The natural history of drug resistant epilepsy: epidemiological considerations. In: Surgical treatment of epilepsy. Epilepsy Res 1992;(Suppl. 5):25-28.
21. Berg A.T., Vickrey B.G., Testa F.M., et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 60 (2006) 73-79
22. Picot M.C., Baldy-Moulinier M., Daurès J.P., Dujols P., and Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 49 (2008) 1230-1238
23. Schmidt D., and Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr 9 (2009) 47-52
24. Schmidt D., and Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
25. Löscher W., and Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs, 1. Epilepsia 47 (2006) 1253-1284
26. Löscher W., Klotz U., Zimprich F., and Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50 (2009) 1-23
27. Schmidt D. Single drug therapy for intractable epilepsy. J Neurol 229 (1983) 221-226
28. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64 (2005) 1868-1873
29. Ramsay R.E., Uthman B., Pryor F.M., et al. Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia 49 (2008) 1180-1185
30. Tellez-Centano J.F., Patten S.B., Jette N., et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 48 (2007) 2336-2344
31. Beyenburg S., Mitchell A.J., Schmidt D., Elger C.E., and Reuber M. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav 7 (2005) 161-171
32. Sillanpää M., and Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: a long-term population-based study of childhood-onset epilepsy. Epilepsy Behav 8 (2006) 713-719
33. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 337 (1991) 1175-1180
34. Berg A.T., and Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 44 (1994) 601-608
35. Todt H. The late prognosis of epilepsy in childhood: results of a prospective follow-up study. Epilepsia 25 (1984) 137-144
36. Tennison M., Greenwood R., Lewis D., and Thorn M. Discontinuing antiepileptic drugs in children with epilepsy: a comparison of a 6 week and a 9 month study period. N Engl J Med 330 (1994) 1407-1410